Eisai Co. Ltd. announced that they will report Q3, 2010 results on February 02, 2010.

Eisai Co. Ltd. reported earnings results for the second quarter ended September 30, 2009. For the quarter, the company registered net sales of JPY 200.3 billion ($2.2 billion) with a 1.3% year-on-year (y/y) decline. The company's sales were mainly thwarted by the disappointing performance in overseas markets especially the United States and Europe, where it was heavily affected by the unfavorable currency fluctuations. However, the cost cutting in both SG&A and R&D sectors served the purpose in the maintenance of sound profit abilities. Operating income was JPY 24.9 billion. Net income was JPY 14.6 billion.

Quintiles Transnational Corp. announced a strategic alliance with Eisai Co. Ltd. to develop six potential oncology products in Eisai's R&D pipeline. Under the terms of the agreement, Quintiles' oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide. The strategic alliance will be structured on a risk-sharing basis, with Quintiles funding, in part, the design and conduct of the clinical studies in exchange for success milestone payments. Other financial terms were not disclosed. The agreement is designed to enable Eisai to extend its oncology program, increasing the number of indications investigated for the six potential products, including eribulin (E7389), E7080, Ontak(R) (denileukin diftitox), E7820, E6201 and E7050. These assets will remain the property of Eisai, with Quintiles having development accountability through the Phase II proof-of-concept stage. In addition to projects covered under the agreement with Quintiles, Eisai will continue ongoing development of 18 additional indications for the same six compounds.